Arresto BioSciences

Palo Alto, United States Founded: 2007 • Age: 19 yrs Acquired By Gilead
Therapeutics for cancer and fibrotic diseases.
Request Access

About Arresto BioSciences

Arresto BioSciences is a company based in Palo Alto (United States) founded in 2007 was acquired by Gilead in December 2010.. Arresto BioSciences operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.

  • Headquarter Palo Alto, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Gilead

    (Dec 20, 2010)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Arresto BioSciences

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Arresto BioSciences

Arresto BioSciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Gilead. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Arresto BioSciences

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Arresto BioSciences

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Arresto Biosciences Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Arresto BioSciences

Arresto BioSciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
domain founded_year HQ Location
Therapeutics for rare and ultra-rare metabolic diseases are developed.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
domain founded_year HQ Location
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Arresto Biosciences

Frequently Asked Questions about Arresto BioSciences

When was Arresto BioSciences founded?

Arresto BioSciences was founded in 2007.

Where is Arresto BioSciences located?

Arresto BioSciences is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.

What does Arresto BioSciences do?

Arresto Biosciences developed therapeutics for cancer and fibrotic diseases. Its drug candidates targeted enzymes that are involves in the synthesis of the extracellular matrix (ECM). Its lead candidate was a humanized monoclonal antibody that targeted human lysyl oxidase-like-2 (LOXL2) and was in phase I trials for both idiopathic pulmonary fibrosis (IPF) and advanced solid tumors. In Dec 2010, Gilead acquired the company for 225M upfront plus milestone payments.

Who are the top competitors of Arresto BioSciences?

Arresto BioSciences's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.

Who are Arresto BioSciences's investors?

Arresto BioSciences has 1 investor. Key investors include Gilead.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available